Fibrosis Models in Mice

Similar documents
Comparative Biosciences Model of Monocrotaline-Induced Pulmonary Hypertension in Rats

Melanin Associated Antigen Induced Uveitis in Rats

Thermal Dermal Burn Modeling in Rats and Minipigs

Preclinical Models of Ocular Glaucoma at CBI

Postnatal Hyperoxia-induced Lung and Retinal Injury in Infant Rats: Qin Zhang, Alireza Ebrahimnejad, Felisha Paniagua, Robert Sukhu, Carol Meschter

Guidance on the GLP Requirements for Peer Review of Histopathology Advisory Document

Approach to the Ethical Review

Longitudinal Validation Study: Streptozotocin-Induced Diabetes as a Model of Diabetic Retinopathy in Brown Norway Rats

Small Molecule Inhibitor of the Wnt Pathway (SM04755) as a Potential Topical Scleroderma Treatment

Update in deposition diseases

Evaluation of Ramazzini Institute Aspartame Studies and EFSA s Assessment

Liver Disease NASH/Fibrosis Model

European Respiratory Society Annual Congress. Presented at: of new drugs for respiratory diseases. Barcelona, Spain, September 7-11, 2013 Page 1

Page 1132

LADIS Case of the Month

Block 1. Immunology and Principles of Vaccination

Supplementary data and figures Thyroid hormone inhibits murine lung fibrosis through improved epithelial mitochondrial function

Supplementary Figure 1: Fn14 is upregulated in the epidermis and dermis of mice

Final Report. Acute dermal toxicity study in Wistar rats. Mr. M. Vasanthan, M Tech (Biotech)

Final Report. Acute oral toxicity study in Wistar rats. Mr. S. Haribabu, B Tech (Biotech), MSc

Programa Cooperación Farma-Biotech Jornada : Zaragoza. Efficacy of P17, a TGFbeta1 inhibitor peptide, in lung fibrosis and melanoma

TERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

Supplemental Figure 1

EHR Developer Code of Conduct Frequently Asked Questions

SHRIRAM INSTITUTE FOR INDUSTRIAL RESEARCH. ACUTE ORAL TOXICITY STUDY IN RATS WITH Cry 1 C a 1 PROTEIN

Women s Reproductive Health Services: Sample Policy and Procedure

2019 Midwest Government Contracting Symposium

Cell Therapy for Lung Indications Choosing the appropriate IND Enabling Animal Model

Potential Rebalancing of the Immune System by Anti-CD52 Therapy

Innovator in Chelated Mineral Nutrition

CYLD Negatively Regulates Transforming Growth Factor-β Signaling via Deubiquitinating Akt

Supplementary Table 1: LP/J C57BL/6 cgvhd scoring. Each category: coat

Progenics Cord Blood Cryobank Monthly Quality Report

Yun-Jung Choi, Jiangao Song, Jeff D. Johnson, Charles McWherter. NASH-TAG Conference Park City, Utah January 4, 2019

KD025 in IPF: Topline Results

In Vitro Models Available for Testing of ENDS. Holger P. Behrsing, Ph.D. Principal Scientist Respiratory Toxicology Program

Committed to Environment, Health, & Safety

Supplemental Data. Epithelial-Macrophage Interactions Determine Pulmonary Fibrosis Susceptibility in. Hermansky-Pudlak Syndrome

Engaging with FDA: A Guide for Foundation Funders of Research. FasterCures Webinar Series presents. April 18, 2012

Inaugural UK IgG4-related disease Symposium. Royal College of Physicians, London

TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression

Test Article Analyses in Compliance with Good Laboratory Practice in Japan: Circumstances and Changes

Comparability and quality of experimental data under different quality systems. S. Caroli Istituto Superiore di Sanità Rome

ECHA Committee for Risk Assessment: Evaluation of the Classification and Labelling of Glyphosate

Rheumatoid Arthritis. Immunology and Inflammatory Disease. In pursuit of your success. Autoimmune Arthritis Animal Models Available:

GLP in the European Union Ecolabel detergents, GLP and accreditation

Retinab for Diabetic Retinopathy

CONFERENCE FOR CATHOLIC FACILITY MANAGEMENT

MEDIA RELEASE FOR IMMEDIATE RELEASE. 15 September 2014

EPA REGULATORY UPDATE

Morphologic and histochemical changes in the skin of patients with scleroderma

AAALAC Perspectives on Performance-based Standards. John Bradfield, DVM, PhD, DACLAM Senior Director, AAALAC International

PRESS RELEASE FOR IMMEDIATE RELEASE SINGAPORE INSTITUTES COLLABORATE WITH SAMSUNG MEDICAL CENTER TO IMPROVE TREATMENT OF LIVER CANCER

i-bodies a new class of protein therapeutics to treat fibrosis

Specific Accreditation Guidance OECD GLP

Nonclinical Safety Evaluation of Inhalation Drug Products

CRYO Science. We handle worldwide enquiries and installations tailored to meet your needs.

About OMICS Group Conferences

Katherine Gibson-Corley DVM, PhD, DACVP. Pathology Grand Rounds March 27, 2014

SHRIRAM INSTITUTE FOR INDUSTRIAL RESEARCH

Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids

MTB-1 MEDIATED GENE REGULATION SHOWS BENEFICIAL EFFECTS IN DMD PATIENT CELLS AND MDX MICE

Financing Influenza Vaccine R&D

Boehringer Ingelheim BioXcellence. Producing Value. Global Contract Manufacturing Excellence

7 Questions To Ask A CARF Consultant Before You Hire

Port of Portland Hillsboro Airport Master Plan Update Planning Advisory Committee Charter

RO-ILS: Radiation Oncology Incident Learning System Congressional Briefing

ATTUD APPLICATION FORM FOR WEBSITE LISTING (PHASE 1): TOBACCO TREATMENT SPECIALIST (TTS) TRAINING PROGRAM PROGRAM INFORMATION & OVERVIEW

AMERICAN ACADEMY OF NEUROLOGY NEUROGENETICS FELLOWSHIP CORE CURRICULUM

ALS ACT (Accelerated Therapeutics)

Supplemental Table 1. Primer sequences for transcript analysis

Best Practice Title: Reporting Programmatic And Repetitive Noncompliances in NTS and SSIMS

FACTORY TOUR SAFETY GUIDE

Allograft Based Breast Reconstruction: Opportunity for a Second Look

Guide to Tobacco-Free Campuses

Darwin Marine Supply Base HSEQ Quality Management Plan

Committed to Environment, Health and Safety

Regulatory Support for Tobacco Products. Feeling daunted by the regulatory process for tobacco products? Don t worry Battelle can help.

Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO

DIA Oligonucleotide-Based Therapeutics Conference

Prepared by GREEN VALLEY RECREATION, INC.

CAELUM BIOSCIENCES. Corporate Overview May, 2017

Highly Pathogenic Avian Influenza:

Interim Results for 6 Months Ended 31 March 2017 and Business Update. 17 th May 2017

Advances in Lung Transplantation & Pulmonary Arterial Hypertension 2014

CARIBX (UK) LIMITED. Environmental, Health and Safety Management System. Revision: 00 APRIL 2011

The Five Key Elements of World-Class EHS and Sustainability Organizations

Supplementary Figure 1. Spitzoid Melanoma with PPFIBP1-MET fusion. (a) Histopathology (4x) shows a domed papule with melanocytes extending into the

California Custom Processing Plant Quality Assurance Plan

Preclinical Experience with rhasm for Niemann-Pick Disease

ISSM, and AUA meetings is expected.

Corporate Presentation

See things more clearly with a Humana vision plan.

ECHO Investment S.A. Echo Investment S.A.

Self Assessment Training. Webinar 2012, Part 1

TITLE DEPARTMENT OF BUSINESS REGULATIONS

Stewardship Report. Presented to. The Harold E. Eisenberg Foundation

Corporate Presentation

FITNESS ATTENDANT (PT)

Transcription:

Fibrosis Models in Mice Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA 94085 Telephone: 408.738.9260 www.compbio.com

Premier Preclinical Contract Research Organization Nearly 20 years of experience Conveniently located in the heart of Silicon Valley, amidst many biotech companies State of the art, purpose-built facility Approximately 30 employees Highly experienced staff GLP, OECD, FDA, USDA, OLAW AAALAC Accreditation

Murine Fibrosis Models Sclerotic Skin (Scleroderma) - Local Repeated Injection of Bleomycin Pulmonary Fibrosis - Continuous SC Infusion of Bleomycin by Osmotic Pump

Sclerotic Skin Model Study Parameters and Sample Data

Sclerotic Skin Model: Typical Parameters C3H females at 7 weeks of age Local SC injection of bleomycin daily for 30 days Test article administration per sponsor Clinical observation daily Weekly body weights Necropsy and histopathology

Sclerotic Skin Model: Sample Data Body Weight (g) 24.0 22.0 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 Body Weights (C3H/HeOuJ) Vehicle 0.01 U Bleomycin 0.1 U Bleomycin 0.3 U Bleomycin 0 7 14 21 28 Day on Bleomycin

Sclerotic Skin Model: Sample Data Histopathologic Score 4.5 4 3.5 3 2.5 2 1.5 1 0.5 0 vehicle Dermal Fibrosis (C3H/HeJ) 0.01 U Bleomycin 0.1 U Bleomycin 0.3 U Bleomycin

Sclerotic Skin Model: Sample Data 5.0 Dermal Fibrosis Histopathologic Score 4.0 3.0 2.0 1.0 vehicle 20 U/kg Bleomycin 100 U/kg Bleomycin 150 U/kg Bleomycin 0.0 4 weeks 6 weeks

Sclerotic Skin Model: Histopathology Left: Trichrome of normal mouse skin, demonstrating low amount of collagen in superficial dermis (blue) Bottom: Bleomycin-treated mouse skin demonstrating large amount of collagen deposition and fibrosis in superficial and deep dermis (blue)

Pulmonary Fibrosis Model Study Parameters and Sample Data

Pulmonary Fibrosis: Typical Parameters C57BL/6 females at 7 weeks of age Surgical implantation of osmotic pump with 7 day constant infusion of bleomycin Clinical observation daily Body weights weekly Necropsy and histopathology

Pulmonary Fibrosis: Sample Data Histopathologic Score 4 3.5 3 2.5 2 1.5 1 0.5 0 Pulmonary Fibrosis and Inflammation (C3H/HeJ) vehicle 0.01 U Bleomycin 0.1 U Bleomycin 0.3 U Bleomycin

Pulmonary Fibrosis: Sample Data Histopathologic Score 4 3.5 3 2.5 2 1.5 1 0.5 0 Pulmonary Fibrosis and Inflammation (C3H/HeOuJ) vehicle 0.01 U Bleomycin 0.1 U Bleomycin 0.3 U Bleomycin

Pulmonary Fibrosis: Sample Data Body Weight (g) 24.0 22.0 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 Body Weights in Bleomycin-treated Mice Vehicle 20 U/kg Bleomycin 100 U/kg Bleomycin 150 U/kg Bleomycin 0 7 14 21 28 35 42 Day on study

Pulmonary Fibrosis: Sample Data Pulmonary Fibrosis and Inflammation Histopathologic Score 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 4 weeks 6 weeks vehicle 20 U/kg Bleomycin 100 U/kg Bleomycin 150 U/kg Bleomycin

Pulmonary Fibrosis: Histopathology Left: Trichrome of normal mouse lung, demonstrating little or no collagen (blue) Bottom: Bleomycin-treated mouse lung demonstrating large amount s of collagen deposition and fibrosis in pulmonary parenchyma and around air ways

Service and Quality Thoroughness in planning and execution is key to a successful study. All protocols are vetted and approved by multiple personnel. Our QAU has a rigorous training program. All non- GLP studies are conducted in the spirit of GLP. We believe in sound science. Our ratio of scientists to nonscientists is one of the highest in the industry. Every study director is a PhD-level scientist. We believe in communication. Timely responses to your inquiries and frequent updates on your study are mandatory. We welcome visitors. You are always welcome at CBI to meet the staff, tour the laboratory and discuss the progress and results of your study.